neosaxitoxin
Small moleculeexperimental
Neosaxitoxin (NSTX) is included, as other saxitoxin-analogs, in a broad group of natural neurotoxic alkaloids, commonly known as the paralytic shellfish toxins (PSTs). The parent compound of PSTs, saxitoxin (STX), is a tricyclic perhydropurine alkaloid, which can be substituted at various positions, leading to more than 30 naturally occurring STX analogues. All of them are related imidazoline guanidinium derivatives. — Wikipedia
Clinical trial activity
3 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
3
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started May 1, 2005 (NCT00273065)
Timeline
2000s
- Jan 1, 2005
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
- Unspecified targetUnclear
unclear
Chemistry & pharmacology
Loading structure…
SMILES
N=C1N(O)[C@@H](COC(N)=O)[C@@H]2N=C(N)N[C@]23N1CCC3(O)O- Mol. weight
- 315.29 g/mol
- Lipinski Ro5
- 1 violation(s)
- Rule of 3
- No
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- WikipediaNeosaxitoxin ↗
- ChEMBLCHEMBL4297307 ↗
Also known as
- neosaxitoxin
- neosaxitoxin
- neosaxitoxin
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT03399435 | Phase 1 | Jan 30, 2018 | Grunenthal |
| NCT01786655 | Phase 1 | May 1, 2013 | Harvard University |
| NCT00273065 | Phase 1 | May 1, 2005 | University of Chile |
Showing 3 of 3 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Grunenthal | For profit | 1 | 1 | 1 | 2018 |
| Harvard University | Academic/Hospital | 1 | 1 | 1 | 2013 |
| University of Chile | Academic/Hospital | 1 | 1 | 1 | 2005 |
3 organizations
Page 1 / 1